NCT03682068 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT03682068
Title	Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer (NILE)
Acronym	NILE
Recruitment	Active, not recruiting
Gender	both
Phase	Phase III
Variant Requirements	No
Sponsors	AstraZeneca
Indications	ureter transitional cell carcinoma bladder urothelial carcinoma renal pelvis transitional cell carcinoma urethra transitional cell carcinoma
Therapies	Carboplatin + Durvalumab + Gemcitabine Carboplatin + Durvalumab + Gemcitabine + Tremelimumab Cisplatin + Durvalumab + Gemcitabine Cisplatin + Durvalumab + Gemcitabine + Tremelimumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine
Age Groups:	senior \| adult
Covered Countries	USA \| TUR \| POL \| ITA \| ISR \| HUN \| ESP \| CZE \| CAN \| BRA \| BGR \| AUS \| ARG

No variant requirements are available.